Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C42H68O13 |
| Molecular Weight | 780.9815 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 21 / 21 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@@H](CC[C@]4(C)[C@@H]3C=C[C@]56OC[C@@]7(CCC(C)(C)C[C@@H]57)[C@@H](O)C[C@@]46C)[C@]2(C)CO)[C@H](O)[C@@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]1O
InChI
InChIKey=KYWSCMDFVARMPN-MSSMMRRTSA-N
InChI=1S/C42H68O13/c1-21-28(46)33(55-34-31(49)30(48)29(47)22(18-43)53-34)32(50)35(52-21)54-27-10-11-37(4)23(38(27,5)19-44)8-12-39(6)24(37)9-13-42-25-16-36(2,3)14-15-41(25,20-51-42)26(45)17-40(39,42)7/h9,13,21-35,43-50H,8,10-12,14-20H2,1-7H3/t21-,22-,23-,24-,25-,26+,27+,28+,29-,30+,31-,32-,33+,34+,35+,37+,38+,39-,40+,41-,42+/m1/s1
Saikosaponin A is a triterpene saponin found in Bupleurum that exhibits anti-inflammatory, analgesic, neuromodulatory, anticancer, and immunosuppressive activities. Saikosaponin A decreases production of TNF-α, IL-1β, and IL-2 and increases mechanical withdrawal thresholds and thermal withdrawal thresholds in animal models of chronic constructive injury. Saikosaponin A also decreases self-administration of cocaine and morphine. In colon carcinoma cells, saikosaponin A causes activation of caspases 2, 3, 8, and 9 and PARP, induces apoptosis, and decreases expression of Bcl-2 and XIAP. Additionally, this compound inhibits the proliferation and activation of ConA-treated T cells, inducing G0/G1 phase cell cycle arrest and decreasing expression of TNF-α, IL-2, and IFN-γ.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28293263 | https://www.ncbi.nlm.nih.gov/pubmed/24076136
Curator's Comment: Saikosaponin A alleviates symptoms of attention deficit hyperactivity disorder in spontaneous hypertensive rats.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL338 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28293263 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25107300 |
Primary | Unknown Approved UseUnknown |
||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25107300
Rats were administered saikosaponin a (6.25, 12.50 and 25.00 mg/kg intraperitoneal, once daily) for 14 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25223791
Saikosaponin A showed the most potent cytotoxicity against human cancer cells (gastric cancer, AGS cells; breast cancer, MCF-7 cells; and hepatoma, HepG2 cells) after 24 h. The IC50 values for the above three cell types were 34.6, 33.3, and 23.4 umol/L, respectively.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00942951
Created by
admin on Mon Mar 31 20:48:49 GMT 2025 , Edited by admin on Mon Mar 31 20:48:49 GMT 2025
|
PRIMARY | |||
|
20736-09-8
Created by
admin on Mon Mar 31 20:48:49 GMT 2025 , Edited by admin on Mon Mar 31 20:48:49 GMT 2025
|
PRIMARY | |||
|
09O6CAG7JV
Created by
admin on Mon Mar 31 20:48:49 GMT 2025 , Edited by admin on Mon Mar 31 20:48:49 GMT 2025
|
PRIMARY | |||
|
167928
Created by
admin on Mon Mar 31 20:48:49 GMT 2025 , Edited by admin on Mon Mar 31 20:48:49 GMT 2025
|
PRIMARY | |||
|
C025759
Created by
admin on Mon Mar 31 20:48:49 GMT 2025 , Edited by admin on Mon Mar 31 20:48:49 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD